Results 51 to 60 of about 93,640 (252)

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease

Annals of Clinical and Translational Neurology, 2020
Objective To determine the evolution of numerous neuropsychiatric symptoms and cognitive abilities in Parkinson disease from disease onset. Methods Prospectively collected, longitudinal (untreated, disease onset to year 5), observational data from ...
Daniel Weintraub, Chelsea Caspell‐Garcia, Tanya Simuni, Hyunkeun R. Cho, Christopher S. Coffey, Dag Aarsland, Roy N. Alcalay, Matthew J. Barrett, Lana M. Chahine, Jamie Eberling, Alberto J. Espay, Jamie Hamilton, Keith A. Hawkins, James Leverenz, Irene Litvan, Irene Richard, Liana S. Rosenthal, Andrew Siderowf, Michele York, Parkinson’s Progression Markers Initiative   +19 more
doaj   +1 more source

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

In silico and in vitro exploration of a tyrosinase for biocatalytic production of catechols

FEBS Open Bio, EarlyView.
Tyrosinase from Ralstonia pseudosolanacearum is a promising biocatalyst for producing valuable catechols from monophenol substrates. This tyrosinase is uniquely suited to this due to its high monophenolase : diphenolase ratio. We combined in silico docking and in vivo kinetic characterisation of this tyrosinase with 11 industrially relevant monophenols,
James Britton, Fang Zhao, Reeta Davis, Meg Walsh, Kevin E O'Connor, David O'Connell, Tanja Narancic   +6 more
wiley   +1 more source

Feasibility of a Pharmabuddy Care Service for patients with Parkinson’s disease

BMC Health Services Research
Background Pharmaceutical care for patients with Parkinson’s disease (PD) is complex. Specialized pharmaceutical care provided by a dedicated pharmacy team member (pharmabuddy) for these patients may reduce medication-related problems. The feasibility of
C. C. M. Stuijt, F. Karapinar-Çarkit, C. van de Steeg – van Gompel, T. van Laar, B. J. F. van den Bemt, M. Heringa   +5 more
doaj   +1 more source

Inhibition of Protease-Activated Receptor-2 Activation in Parkinson’s Disease Using 1-Piperidin Propionic Acid

Biomedicines
In Parkinson’s disease, neuroinflammation is a double-edged sword; when inflammation occurs it can have harmful effects, despite its important role in battling infections and healing tissue.
Santina Quarta, Michele Sandre, Mariagrazia Ruvoletto, Marta Campagnolo, Aron Emmi, Alessandra Biasiolo, Patrizia Pontisso, Angelo Antonini   +7 more
doaj   +1 more source

No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors

Translational Neurodegeneration, 2019
Background IgG-class autoantibodies to N-Methyl-D-Aspartate (NMDA)-type glutamate receptors define a novel entity of autoimmune encephalitis. Studies examining the prevalence of NMDA IgA/IgM antibodies in patients with Parkinson disease with/without ...
Franziska Hopfner, Stefanie H. Müller, Dagmar Steppat, Joanna Miller, Nele Schmidt, Klaus-Peter Wandinger, Frank Leypoldt, Daniela Berg, Andre Franke, Wolfgang Lieb, Lukas Tittmann, Monika Balzer-Geldsetzer, Simon Baudrexel, Richard Dodel, Ruediger Hilker-Roggendorf, Elke Kalbe, Jan Kassubek, Thomas Klockgether, Inga Liepelt-Scarfone, Brit Mollenhauer, Petra Neuser, Kathrin Reetz, Oliver Riedel, Claudia Schulte, Jörg B. Schulz, Annika Spottke, Alexander Storch, Claudia Trenkwalder, Hans-Ulrich Wittchen, Karsten Witt, Ullrich Wüllner, Günther Deuschl, Gregor Kuhlenbäumer   +32 more
doaj   +1 more source

Long‐Term Follow‐Up of Chemotherapy‐Associated Biological Aging in Women With Early Breast Cancer

Aging and Cancer, EarlyView.
Women threated with adjuvant chemotherapy for early breast cancer have sustained long‐term increase in p16INK4a,, a robust marker of cell senescence, suggesting a chemotherapy‐associated age acceleration. p16INK4a as well as other biomarkers may identify patients at greatest risk for senescence‐related diseases of aging.
Hyman B. Muss, Alexis C. Wardell, Allison M. Deal, Kirsten A. Nyrop, Allison Ross, Yara G. Abdou, Jeffrey D. Aldrich, Lisa A. Cary, E. Claire Dees, Katherine E. Reeder‐Hayes, Emily M. Ray, Natalia Mitin, Denis Tsygankov   +12 more
wiley   +1 more source

Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level

Aging and Cancer, EarlyView.
This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley   +1 more source

Parkinson's disease [PDF]

The Lancet, 2004
Parkinson's disease is the most common serious movement disorder in the world, affecting about 1% of adults older than 60 years. The disease is attributed to selective loss of neurons in the substantia nigra, and its cause is enigmatic in most individuals.
Samii, Ali, Nutt, John G., Ransom, Bruce R.   +2 more
openaire   +3 more sources

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi, Caroline Gochanour, Seung Ho Choi, Hyunkeun Cho, Chelsea Caspell‐Garcia, Christopher Coffey, Michael Brumm, David‐Erick Lafontant, Yuge Xiao, Thomas Tropea, John Seibyl, Caroline Tanner, Charles S. Venuto, Karl Kieburtz, Lana M. Chahine, Kathleen L. Poston, Andrew Siderowf, Kenneth Marek, Tanya Simuni, The Parkinson's Progression Markers Initiative   +19 more
wiley   +1 more source